Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) currently has a daily average trading volume of 93.26K but it saw 14548124 shares traded in last market. With a market cap of 35.83M USD, the company’s current market price of $1.90 came falling about -1.55 while comparing to the previous closing price of $1.93. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.55 and as low as $0.55.
Taking a look at 20-day trading activity of Chemomab Therapeutics Ltd ADR (CMMB) gives us an average price of $2.0326, while its current price level is -25.49% below from 52-week high level whereas it is 244.83% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.9431 while that of 200 days or SMA-200 reads an average of $1.4733. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.81% during that period while stretching the period over a month that decreases to 7.12%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 42.77 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Maxim Group which initiated the stock as “Buy” in its note to investors issued on May 13, 2024, recommending a price target of $4 for it. Oppenheimer upgraded its recommendation for the stock as a “Outperform” from “Perform” on May 06, 2024 while assigning a price target of $6. ROTH MKM issued its recommendations for the stock as it resumed the price target for the stock is $7.
Over the week, CMMB’s stock price is moving -1.63% down while it is -11.21% when we observe its performance for the past one month. Year-to-date it is 4.97% up and over the past year, the stock is showing an upside performance of 211.48%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -0.01 while estimate for next year EPS is -0.05.
Currently, Chemomab Therapeutics Ltd ADR’s total number of outstanding shares is 18.86M with 15.91% of that held by the insiders while 25.92% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -87.48% and return on equity (ROE) at -84.26%. Stock’s beta reads 0.51. Stock has a price to book (P/B) ratio of 2.20. Its return on asset (ROA) is -65.33% on average.
